See more : Scepter Holdings, Inc. (BRZL) Income Statement Analysis – Financial Results
Complete financial analysis of Inozyme Pharma, Inc. (INZY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Inozyme Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Power Minerals Limited (PEIMF) Income Statement Analysis – Financial Results
- Anhui Sunhere Pharmaceutical Excipients Co.,Ltd. (300452.SZ) Income Statement Analysis – Financial Results
- Kape Technologies PLC (KAPE.L) Income Statement Analysis – Financial Results
- AfterMaster, Inc. (AFTM) Income Statement Analysis – Financial Results
- COL Digital Publishing Group Co., Ltd. (300364.SZ) Income Statement Analysis – Financial Results
Inozyme Pharma, Inc. (INZY)
About Inozyme Pharma, Inc.
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.29M | 1.18M | 1.05M | 217.00K | 83.00K | 26.00K |
| Gross Profit | -1.29M | -1.18M | -1.05M | -217.00K | -83.00K | -26.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 54.85M | 47.85M | 37.72M | 46.49M | 16.22M | 8.10M |
| General & Administrative | 20.80M | 20.83M | 18.93M | 10.55M | 4.59M | 3.49M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.80M | 20.83M | 18.93M | 10.55M | 4.59M | 3.49M |
| Other Expenses | 0.00 | -319.00K | -189.00K | 247.00K | -24.00K | 4.35M |
| Operating Expenses | 75.65M | 68.68M | 56.65M | 57.04M | 20.81M | 11.59M |
| Cost & Expenses | 75.65M | 68.68M | 56.65M | 57.04M | 20.81M | 11.59M |
| Interest Income | 7.84M | 1.93M | 211.00K | 370.00K | 1.11M | 284.00K |
| Interest Expense | 3.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 833.00K | 1.18M | 1.05M | 217.00K | 83.00K | 26.00K |
| EBITDA | -74.81M | -65.88M | -55.97M | -56.82M | -20.72M | -11.57M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -75.65M | -68.68M | -56.65M | -57.04M | -20.81M | -11.59M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.48M | 1.61M | 22.00K | 617.00K | 1.08M | 4.63M |
| Income Before Tax | -71.17M | -67.06M | -56.62M | -56.42M | -19.72M | -6.96M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.61M | -211.00K | -587.00K | -1.11M | 4.63M |
| Net Income | -71.17M | -65.45M | -56.41M | -55.84M | -18.62M | -6.96M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.37 | -1.73 | -2.39 | -2.39 | -1.23 | -0.46 |
| EPS Diluted | -1.37 | -1.73 | -2.39 | -2.39 | -1.23 | -0.46 |
| Weighted Avg Shares Out | 51.84M | 37.76M | 23.56M | 23.38M | 15.16M | 15.14M |
| Weighted Avg Shares Out (Dil) | 51.84M | 37.76M | 23.56M | 23.38M | 15.16M | 15.14M |
Inozyme Pharma: Rare Disease Player Merits Revaluation Higher After POC Data
Shares are down 58% over the past year. Enzyme replacement therapy is an attractive area of drug development with less risk than more exotic modalities like gene therapy.
Choosing Penny Stocks for Short Term Trading; 3 Tips
Use these tips for trading penny stocks in the short term The post Choosing Penny Stocks for Short Term Trading; 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Inozyme Pharma to Participate in Upcoming Investor Conferences
BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that Axel Bolte, MSc, MBA, the company's co-founder,...
Inozyme Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference
BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive officer, will...
Inozyme Pharma Post Encouraging Early Data From Genetic Disorder Trial
Inozyme Pharma Inc (NASDAQ: INZY) has announced preliminary biomarker, safety, and pharmacokinetic (PK) data from the first three subjects in the Phase 1 portion of its ongoing Phase 1/2 trial of INZ-701 in ABCC6 Deficiency, which presents as pseudoxanthoma elasticum (PXE) in older.
How Much Upside is Left in Inozyme Pharma, Inc. (INZY)? Wall Street Analysts Think 309%
The consensus price target hints at a 308.5% upside potential for Inozyme Pharma, Inc. (INZY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness...
Inozyme Pharma to Present at the 2022 Jefferies Healthcare Conference
BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive...
Inozyme Pharma Starts Dosing In INZ-701 Trial For Calcification Disorders
Inozyme Pharma Inc (NASDAQ: INZY) has dosed the first patient in its Phase 1/2 trial of INZ-701 in adult patients with ABCC6 Deficiency. Also, the second cohort in the ongoing Phase 1/2 clinical trial in ENPP1 Deficiency has been fully enrolled.
Inozyme Pharma to Present at the 21st Annual Needham Virtual Healthcare Conference
BOSTON, April 06, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive officer, will...
Why Inozyme Pharma Shares Are Jumping Today
Inozyme Pharma Inc (NASDAQ: INZY) announced preliminary biomarker, safety, and pharmacokinetic (PK) data from the first three patients treated in the Phase 1 portion of its Phase 1/2 trial of INZ-701 in ENPP1 Deficiency. ENPP1 Deficiency manifests generalized arterial.
Source: https://incomestatements.info
Category: Stock Reports